Drugs / JNJ-18038683
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT02466685 | Sep 2015 → Sep 2021 | bipolar disorder | Herbert Meltzer | Completed | No outcome recorded |
| Phase 2 | NCT00566202 | Dec 2007 → Dec 2008 | major depressive disorder | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03633357 | Aug 2018 → Jun 2022 | bipolar disorder | King's College London | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-18038683 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03633357 ↗ |
| Action | Inhibit | “The 5-HT7 receptor antagonist, JNJ-18038683, has been reported to be effective in rodent models of depression and REM sleep.” PMID 39250138 ↗ Sep 20241“Serotonin 7 (5-HT7) receptor antagonist” CHEMBL4205783 ↗ |
| Modality | Small molecule | — CHEMBL4205783 ↗ |
| Route | Oral | “Administration: Oral” NCT03633357 ↗ |
| Target | HTR7 | “Serotonin 7 (5-HT7) receptor antagonist” CHEMBL4205783 ↗ |